Cel Sci (CVM) Enterprise Value (2010 - 2026)
Cel Sci (CVM) posted Enterprise Value of -$1.9 million for Q1 2026, up 69.79% sequentially from -$6.3 million in Q4 2025, and up 1.72% YoY from -$1.9 million in Q1 2025.
Cel Sci (CVM) Enterprise Value (2010 - 2026) Analysis & Trends
Cel Sci has reported Enterprise Value for 17 years, with the latest figure at -$1.9 million in Q1 2026.
- Quarterly Enterprise Value rose 1.72% year-over-year to -$1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.9 million (up 1.72% YoY) and the FY2025 annual result came in at -$11.0 million, down 131.15% from the prior year.
- Enterprise Value advanced to -$1.9 million in Q1 2026 per CVM's latest filing, from -$6.3 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$435781.0 in Q2 2024 and troughed at -$34.3 million in Q1 2022.
- A 5-year average of -$9.6 million and a median of -$5.1 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 91.51% in 2024, then plunged 313.13% in 2025.
- Over 5 years, Enterprise Value stood at -$18.0 million in 2022, then surged by 81.92% to -$3.3 million in 2023, then tumbled by 41.87% to -$4.6 million in 2024, then slumped by 35.98% to -$6.3 million in 2025, then soared by 69.79% to -$1.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$1.9 million, -$6.3 million, and -$11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | Cel Sci | 2.18 Mn | -4.36 Mn | - | -6.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.90 Mn |
| Dec 31, 2025 | -6.28 Mn |
| Sep 30, 2025 | -10.96 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Mar 31, 2025 | -1.93 Mn |
| Dec 31, 2024 | -4.62 Mn |
| Sep 30, 2024 | -4.74 Mn |
| Jun 30, 2024 | -435,781.00 |
| Mar 31, 2024 | -5.33 Mn |
| Dec 31, 2023 | -3.26 Mn |
| Sep 30, 2023 | -4.15 Mn |
| Jun 30, 2023 | -5.14 Mn |
| Mar 31, 2023 | -10.05 Mn |
| Dec 31, 2022 | -18.02 Mn |
| Sep 30, 2022 | -22.67 Mn |
| Jun 30, 2022 | -28.07 Mn |
| Mar 31, 2022 | -34.28 Mn |
| Dec 31, 2021 | -37.11 Mn |
| Sep 30, 2021 | -42.21 Mn |
| Jun 30, 2021 | -47.11 Mn |